Progress in the development of vaccines for hepatitis C virus infection
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (42) , 11984-2002
Abstract
The hepatitis C virus (HCV), first described in 1989, is now a leading cause of liver cirrhosis and hepatocellular carcinoma. With more than 170 million people infected globally, this virus is a major public health issue. The current standard therapy is based on interferon in combination with ribavirin. This costly therapy often fails to completely clear the infection and is associated with adverse side effects. Recent anti-HCV therapies are interferon-free direct-acting antiviral (DAA) regimens for HCV, including simeprevir, sofosbuvir, and ledipasvir, which have effects on non-structural proteins. DAA regimens have several advantages, such as specifically targeting HCV viral replication, accompanied by very high sustained virological response rates and lower side effects like flu-like syndrome. These facts plus the fact that most HCV cases progress to chronic infection suggest the potential need for an efficient HCV vaccine. Different innovative methods, including methods based on peptide, recombinant protein, DNA, vector-based, and virus-like particles, have been introduced for the development of HCV vaccines. An extensive number of studies have been published on these vaccines, and some vaccines were even tested in clinical trials. In the current review, progress in the development of preventive and therapeutic vaccines against the HCV is reviewed in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines and viral vectors expressing HCV genes.Keywords
This publication has 230 references indexed in Scilit:
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- Activation of chemokine and inflammatory cytokine response in hepatitis C virus–infected hepatocytes depends on toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediatesHepatology, 2011
- Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutationsHepatology, 2011
- Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytesHepatology, 2011
- A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individualsJournal of Hepatology, 2010
- Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsVaccine, 2010
- Recognition of viruses by cytoplasmic sensorsCurrent Opinion in Immunology, 2010
- CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virusHepatology, 2006
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- Evasion of intracellular host defence by hepatitis C virusNature, 2005